Atara reports Q3 2026 results as tab-cel BLA resubmission moves toward March 2027 FDA decision
The FDA has accepted Atara's resubmitted BLA for tabelecleucel in EBV+ PTLD, with a target action date of March 31, 2027, and approval would trigger a $31 million milestone from Pierre Fabre.
SEC filing